Executive Summary
Staar Surgical (STAA) experienced a 4.07 % rise in its share price during the 24‑hour period ending 03:47 PM Central Europe time on Friday, 23 March 2026. The stock is currently trading at USD 22.48 on major exchanges, representing a 13.59 % gain versus the close at the end of the previous month. With a market capitalization of USD 1.1 billion and a daily volume of USD 9.3 million, the company is firmly positioned within the high‑margin vision‑care niche.
Market Metrics
| Metric | Value |
|---|---|
| Current Price | USD 22.48 |
| Market Capitalization | USD 1.1 bn |
| Shares Outstanding | 49.8 mn |
| Daily Volume | USD 9.3 mn |
| 200‑Day SMA | USD 23.54 |
| 52‑Week High | USD 35.87 (14 May 2026) |
| 52‑Week Low | USD 15.59 (17 Feb 2026) |
The price sits USD 1.06 below the 200‑day moving average, suggesting a potential for further upside if the current bullish momentum continues. The recent 13.59 % month‑to‑date gain places Staar ahead of most peers in the healthcare‑equipment segment, underscoring investor confidence in its product pipeline and revenue diversification.
Peer Performance Snapshot (Last 24 Hours)
| Ticker | Movement | Current Price | Market Cap | P/E (if available) |
|---|---|---|---|---|
| USPH | +2.84 % | USD 87.77 | USD 1.3 bn | 490.95 |
| LBRX | –4.32 % | USD 38.62 | USD 1.3 bn | – |
| HBT/D | –0.98 % | USD 36.63 | USD 1.3 bn | 15.18 |
| FOR | +3.97 % | USD 26.22 | USD 1.3 bn | 7.60 |
| RAPP | –14.67 % | USD 26.49 | USD 1.3 bn | – |
While Staar’s contemporaries exhibit mixed movements, the company’s upward trajectory is reinforced by a robust operating model and a strong foothold in both refractive and cataract‑surgery markets.
Insider Activity at Rapport Therapeutics
On 22 October 2026, Rapport Therapeutics (RAPP) disclosed several beneficial‑ownership filings. Senior officers and directors—including CFO Troy Ignelzi, directors Paul M. Silva, Wendy B. Young, and John M. Maraganore—purchased substantial share blocks ranging from 5,500 to 9,400 shares each, totaling ≈ 77,000 shares held by Paul Capital Strategy III Fund LLC. These transactions demonstrate continued insider conviction in RAPP’s long‑term prospects, despite the stock’s recent –14.67 % decline. Analysts remain divided, with ratings spanning from buy to sell and adjusted price targets reflecting the company’s evolving pipeline.
Strategic Outlook for Staar Surgical
Staar’s portfolio spans high‑margin implantable contact lenses, cataract‑surgery devices, and glaucoma‑surgery instruments. The company’s emphasis on innovation—particularly in myopia‑control lenses—aligns with global trends toward non‑surgical vision correction. With a NASDAQ listing and a solid revenue base, Staar is positioned to capitalize on:
- Expanding cataract‑surgery volumes as aging demographics increase demand.
- Regulatory approvals for next‑generation contact lenses targeting early‑onset myopia.
- Strategic partnerships with ophthalmology networks to broaden distribution.
Investors should monitor the 200‑day moving average as a key technical indicator, while keeping an eye on upcoming earnings releases for guidance on revenue growth and margin expansion.
Conclusion
Staar Surgical’s recent market performance—highlighted by a 4.07 % intraday rally and a 13.59 % month‑to‑date gain—underscores its resilient position in the vision‑care sector. With a diversified product line, solid capital structure, and a forward‑looking pipeline, the company is poised to deliver sustained shareholder value.
